Abivax Surges 10.1%: A 52-Week Rally Amid Phase 3 Hopes and Sky-High Volatility

Summary
• Abivax (ABVX) surges 10.1% intraday to $111.76, hitting a 52-week high of $112.91
• Turnover skyrockets at 1.56% of float, signaling strong retail and institutional participation
• The stock is riding a 587.8% 1-month rally, fueled by phase 3 data and a potential label expansion for obefazimod

Abivax’s intraday surge reflects growing optimism around its lead drug candidate, obefazimod, in ulcerative colitis. With the stock climbing over 10% within hours and trading near its 52-week peak, the market is clearly responding to a convergence of positive clinical data, institutional attention, and speculative momentum. As the biotech sector remains volatile, ABVX is carving its own bullish path, driven by a mix of near-term catalysts and long-term pipeline potential.

Positive Phase 3 Data and Label Expansion Potential Drive ABVX
Abivax’s stock has surged due to continued positive momentum from its phase 3 clinical trial of obefazimod in ulcerative colitis, which demonstrated clinical remission in a significant portion of patients, including those previously unresponsive to JAK inhibitors. The company is now awaiting data from a maintenance study in the second quarter of 2026, which could determine the long-term viability of the drug and its potential for broader label expansion. Additionally, the company’s strong institutional ownership and analyst coverage have amplified the stock's volatility, as investors closely watch for further catalysts that could unlock its market potential. With the stock now trading near its 52-week high, the bullish sentiment is clearly driven by a combination of near-term clinical updates and speculative trading around possible regulatory pathways and partnerships.

Biotech Sector in Focus: Abivax Outperforms Peers with Pipeline-Driven Volatility
While the broader biotech sector remains mixed, Abivax has outpaced its peers like Teva Pharmaceutical Industries (TEVA) and Genmab (GMAB) in terms of recent performance. Moderna (MRNA), a top biotech name, is also up 6.7%, but Abivax’s 587.8% 1-month gain stands out as one of the most significant moves in the sector. The company's stock is now valued at $8.12B, up from a 52-week low of $4.77, indicating strong speculative interest. Unlike larger biotechs with diversified pipelines or blockbuster drugs, Abivax is currently riding the momentum of a single high-potential candidate, making its stock more susceptible to both outsized gains and risks.

Call Options and Key Resistance Levels: Positioning for a Volatile Biotech Play
• 200-day average: $90.47 (well below current price), indicating a long-term bullish trend
• RSI: 35.16 (oversold territory), suggesting potential for a short-term rebound
• MACD: -3.41 (below signal line -1.65), indicating bearish momentum but potential for reversal
• Bollinger Band Middle: $114.30, suggesting a near-term target for continuation
Abivax is currently trading above key resistance levels and within an oversold RSI range, signaling possible short-term upside. The stock remains in a short-term bearish trend but is within a long-term range, making it a high-risk/high-reward trade. Given the high volatility and speculative nature of ABVX, leveraged or directional options could be a more suitable play than a direct equity position.
Top Option 1: ABVX20260410C105
• Contract code: ABVX20260410C105
• Type: Call
• Strike price: $105
• Expiration date: 2026-04-10
• Implied volatility ratio: 52.72% (moderate)
• LVR (Leverage Ratio): 13.18%
• Delta: 0.7776 (high)
• Theta: -0.4496 (large time decay)
• Gamma: 0.0291 (moderate sensitivity to price movement)
• Turnover: 105,064

This option stands out for its high delta, moderate gamma, and solid turnover, making it a strong short-term bet if Abivax breaks above $105 and continues its bullish trend. Assuming a 5% upside (target $117.35), the option payoff would be $12.35 per contract. This makes it ideal for aggressive bulls expecting a continuation of the recent rally.
Top Option 2: ABVX20260410C109
• Contract code: ABVX20260410C109
• Type: Call
• Strike price: $109
• Expiration date: 2026-04-10
• Implied volatility ratio: 16.90% (low)
• LVR (Leverage Ratio): 32.75%
• Delta: 0.8369 (high)
• Theta: -0.3939 (moderate time decay)
• Gamma: 0.0750 (high sensitivity to price movement)
• Turnover: 1,122

This option offers the highest gamma of the selected contracts, making it ideal for a sharp price movement in the next few days. It is well-positioned if the stock breaks out above $109 and continues toward the 52-week high. Assuming a 5% upside (target $117.35), the payoff would be $8.35 per contract. This contract is best for those anticipating a breakout and willing to ride the volatility.
Aggressive bulls may consider ABVX20260410C105 into a break above $105, while ABVX20260410C109 offers high gamma potential for a sharp move toward $112.91.

Backtest Abivax Stock Performance
The backtest of ABVX's performance following a 10% intraday increase from 2022 to now shows a significant strategy return of 419.72%, vastly outperforming the benchmark return of 50.88%. The strategy's excess return is 368.84%, indicating a substantial gain relative to the benchmark. With a CAGR of 98.00%, the strategy demonstrates robust growth over the period. However, it comes with high volatility, a maximum drawdown of 68.82%, and a Sharpe ratio of 0.81, suggesting a risky but potentially rewarding investment profile.

Abivax on the Cusp of a Breakout: Watch for $115 Next
Abivax has shown significant upside momentum, with a 10.1% intraday rally and a 587.8% surge in just one month. As it approaches key resistance at $114.30 (Bollinger Band Middle) and $112.91 (52-week high), the next few days will be critical in determining whether the stock can sustain its bullish trend. The most immediate watchpoint is a break above $114.30, which would confirm a continuation of the rally and open the door to a potential move toward $120. For now, aggressive bulls should consider ABVX20260410C105 as a high-probability call play into the next potential breakout. Meanwhile, Moderna (MRNA) is up 6.7%, reinforcing the biotech sector’s positive momentum and offering a broader bullish backdrop for ABVX.